EUVIMEDEUVIMED entdecken
Crossref

Gut microbiota metabolites and microbiota-targeted interventions in bone metabolism: from SCFAs and TMAO to probiotics and FMT

Zhihui Huang iD, Zhigang Li, Fan Wu, Dabiao Zhou

Postgraduate Medical Journal · 28.07.2026

DOI: 10.1093/postmj/qgag099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postgraduate Medical Journal, online erschienen am 28.07.2026. Verfasst von Zhihui Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedics Department, Jiaxing Xiuzhou District People's Hospital, Jiaxing, Zhejiang, 314000, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accumulating evidence supports a microbiota-gut-bone axis in which intestinal microbes influence skeletal remodeling through barrier integrity, immune signaling, and metabolite production.

Methods

This review emphasizes specific metabolites, strain-level intervention data, and translational limitations.

Results

Preclinical studies consistently show that dysbiosis, barrier disruption, and altered microbial metabolites promote osteoclastogenesis and suppress osteoblast function. Among short-chain fatty acids, propionate and butyrate have the strongest direct anti-osteoclast evidence, whereas acetate a bone-relevant systemic substrate/signaling molecule with context-dependent skeletal effects. Trimethylamine N-oxide has been linked mechanistically to impaired osteogenic commitment of bone marrow stromal cells and inflammatory signaling, although human epidemiologic findings are not uniform. These mechanisms appear particularly relevant in postmenopausal osteoporosis and glucocorticoid-induced osteoporosis, where estrogen deficiency or glucocorticoid exposure amplifies intestinal permeability, inflammatory tone, and microbial dysbiosis. In humans, the clinical signal is promising but heterogeneous. Fecal microbiota transplantation remains largely preclinical in bone disease and faces major challenges in donor selection, protocol standardization, timing, and long-term safety.

Conclusions

Overall, the field is moving from associative observations toward causal and precision-oriented models, but large, well-phenotyped human studies integrating metagenomics, metabolomics, proteomics, and host clinical data are still needed before microbiota-targeted therapies can be routinely incorporated into osteoporosis care.

Schlagwörter

Stichwörter der Autor:innen

fecal microbiota transplantationgut microbiotaosteoporosisprobioticsshort-chain fatty acidstrimethylamine N-oxide

Autor:innen und Institutionen

  • Orthopedics Department, Jiaxing Xiuzhou District People's Hospital, Jiaxing, Zhejiang, 314000, China.
  • Orthopedics Department, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, Wuhan, Hubei, 430015, China.
  • Orthopedics Department, Wuhan University of Science and Technology, Geriatric Hospital Affiliated, Wuhan, Hubei, 430205, China.
  • Orthopedics Department, Wuhan Jiangxia Hospital of Traditional Chinese Medicine , Wuhan, Hubei, 430200, China.

ORCID-Profile: Zhihui Huang

Zitieren

APA

Huang, Z., Li, Z., Wu, F., & Zhou, D. (2026). Gut microbiota metabolites and microbiota-targeted interventions in bone metabolism: from SCFAs and TMAO to probiotics and FMT. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgag099

Vancouver

Huang Z, Li Z, Wu F, Zhou D. Gut microbiota metabolites and microbiota-targeted interventions in bone metabolism: from SCFAs and TMAO to probiotics and FMT. Postgraduate Medical Journal. 2026. doi:10.1093/postmj/qgag099

BibTeX
@article{Huang2026,
  author = {Huang, Zhihui and Li, Zhigang and Wu, Fan and Zhou, Dabiao},
  title = {Gut microbiota metabolites and microbiota-targeted interventions in bone metabolism: from SCFAs and TMAO to probiotics and FMT},
  journal = {Postgraduate Medical Journal},
  year = {2026},
  doi = {10.1093/postmj/qgag099}
}
Kostenlos starten →